Dementia Big
Today, the global healthcare company Merck has announced that it is stopping the EPOCH study, a phase 2/3 study evaluating Verubecestat in people with mild-to-moderate Alzheimer’s disease.
http://ift.tt/2kyCrMR
Wednesday, February 15, 2017
Alzheimer's Society responds to Merck announcement on Verubecestat study
Alzheimer's Society responds to Merck announcement on Verubecestat study:
http://ift.tt/2kyCrMR
http://ift.tt/2kyCrMR
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment